Lister Andrew, Abrey Lauren E, Sandlund John T
St. Bartholomew's Hospital, West Smithfield, London, United Kingdom.
Hematology Am Soc Hematol Educ Program. 2002:283-96. doi: 10.1182/asheducation-2002.1.283.
Central nervous system involvement with malignant lymphoma whether primary or secondary is an uncommon but not rare complication observed in the management of patients with hematological malignancy. Its importance lies in the considerable morbidity and mortality with which it is associated and the inadequacy of therapy. In Section I, Dr. Lauren Abrey addresses the totality of the problem of primary central nervous system lymphoma, with emphasis on strategies increasingly dependent on systemic chemotherapy. In Section II, Dr. John Sandlund reviews the success of sequential clinical trials of overall therapy for acute lymphoblastic leukemia in childhood, identifying those patients at high risk of central nervous system leukemia and the development of a rational therapeutic strategy for prevention. In Section III, Dr. Andrew Lister discusses the issue of secondary central nervous system involvement with lymphoma and the indications for prophylaxis.
恶性淋巴瘤累及中枢神经系统，无论是原发性还是继发性，在血液系统恶性肿瘤患者的治疗中都是一种不常见但并非罕见的并发症。其重要性在于与之相关的相当高的发病率和死亡率以及治疗的不足。在第一部分，劳伦·阿布雷博士阐述了原发性中枢神经系统淋巴瘤这一整体问题，重点是越来越依赖全身化疗的策略。在第二部分，约翰·桑德伦德博士回顾了儿童急性淋巴细胞白血病整体治疗的系列临床试验的成功之处，确定了那些有中枢神经系统白血病高风险的患者，并制定了合理的预防治疗策略。在第三部分，安德鲁·利斯特博士讨论了淋巴瘤继发性累及中枢神经系统的问题以及预防的指征。
